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particularly in the recent years when used as a rescue for
failed initial UCBT. Use of a CBU allows quick second trans-
plants and thus decreases the overall duration of cytopenias.
Second UCBT should be offered as a viable option for children
with a failed ﬁrst UCBT.17
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Objective:We studied the outcome of heavily pre transfused
aplastic anemia patients receiving peripheral blood stem cell
transplant (PBSCT) from matched sibling donor.
Material: 72 consecutive blood/marrow stem cell trans-
plants in 69 aplastic anemia patients over a period of 10 years
in non HEPA ﬁltered single rooms were recorded. Fludar-
abine 30 mg/m
ˇ
2 D-10 to D-5, cyclophosphamide 60 mg/kg/
day D-6 to D-5 and antithymocyte globulin 30 mg/kg/day D-
4 to D-1 were used as conditioning regimen. Cyclosporine
and methotrexate were used for graft versus host disease
(GvHD) prophylaxis. ABO mismatched marrows underwent
RBC depletion. No attempt to reduce antibody titres was
done for ABO mismatched PBSCT.
Results: 63 patients underwent PBSCT; 2 underwent the
procedure twice, 1 of whom had relapsed as acute myeloid
leukemia. Of the 6 patients who received bone marrow stem
cells, 2 relapsed and 1 underwent a successful PBSCT from
the same donor. The median age of patients was 30 years
(range 4-40 years); median time to transplant was 13.5
months (range 1-65 months); median transfusions before
transplant were 22.5 (range 3-10). 28 (38.8%) patients had
pre-existing infections at time of transplant. 65 patients
received empirical antibiotics and 27 received empirical
antifungals for febrile neutropenia during transplant. Posi-
tive blood culture for bacteria was recorded in 10 patients
and a biopsy proven fungus (2 aspergillus, 2 mucor) in 4Figure 1a. Overall survival (OS) in months of 9 patients with SCA after Reduced Toxic
4-45 mo).patients; 5 other patients had possible fungal infection based
on radiological features.
All patients and donors were CMV IgG positive at base-
line. CMV reactivation was noted in 11 patients, 5 of whom
were on steroids for GVHD; 3 patients subsequently suffered
a graft failure.
55/72 (76%) patients are alive at median follow-up of 60
months ranging from 0-118 months. Acute GVHD was seen in
18/72 transplants (25%). 5 patients developed grade III-IV gut
acute GvHD; 4 died. Chronic GvHD was seen in 32% of cases
(20/62; 10 patients died before day 100). However these were
mostly associated with dry skin and changes in pigmentation
which generally subsided over time and well tolerated;1 pa-
tient had nephrotic syndrome at 3 years. Severe cGVHD as per
NIH criteria was seen in only 5 patients. 17 patients had ABO
major mismatch of which 5 patients developed PRCA. PRCA
was managed with steroids and erythropoietin; the longest
duration before recovery was 12 months. 17 patients died.
Cause of early death (<day 100) were: acute GVHD 4, intra-
cranial bleed 4, aspergillus 1, CMV 1, graft rejection 5 (more
than 1 possible cause in some). Cause of death > day 100:
chronic GVHD 1, graft rejection 2, tuberculosis 1.
Conclusions: PBSCT is safe in aplastic anemia patients whose
transplant has been delayed and thereby heavily pre-
transfused. The outcome and survival appear comparable to
those achieved with historical bone marrow transplant data
without apparent increase in morbidity on account of
chronic GvHD.18
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